Intellect Neurosciences

What Intellect Neurosciences does

Intellect Neurosciences, Inc. is a Manhattan-based, clinical-stage biopharmaceutical company founded in 2005 by Dr. Daniel Chain to develop disease-modifying therapeutics for proteinopathies affecting the brain and eye, with initial focus on Alzheimer's disease and subsequent expansion into Friedreich's Ataxia and age-related macular degeneration. The company's scientific platform rests on four core technology families: ANTISENILIN® (small-molecule and antibody approaches targeting soluble amyloid-beta), RECALL-VAX™ (neoepitope-based immunotherapy), CONJUMAB-A (antibody-drug conjugates combining monoclonal antibodies with anti-oxidant and anti-inflammatory payloads), and TOC-1 (a monoclonal antibody selective for pre-fibrillar tau aggregates). Multiple programs derived from these platforms have been licensed to major pharmaceutical companies and are in Phase 1, Phase 2 and Phase 3 clinical trials, with the ViroPharma partnership for Friedreich's Ataxia disclosed at up to $120 million in milestones plus double-digit royalties.

The business model is asset-light and licensing-centric rather than commercial: Intellect maintains 1-10 employees, outsources R&D to academic centers and contract research organizations nationally and internationally, and develops drug programs to value-inflection points before out-licensing them to large pharmaceutical partners for clinical advancement and commercialization. Revenue, to the extent any exists, takes the form of milestone payments and royalties on licensed products rather than product sales. The company's customer base is effectively large pharmaceutical companies (with ViroPharma as the most prominently disclosed counterparty), while the end patient population consists of individuals with Alzheimer's disease, Friedreich's Ataxia, AMD, and other neurodegenerative conditions.

Intellect's IP position spans the United States, Europe, Japan and several other jurisdictions, with granted patents covering ANTISENILIN, insulin sensitizers for memory loss and dementia, and a 2013 USPTO allowance for TOC-1. The capital structure is publicly traded on otcpink under ticker ILNS following a delisting from OTCBB, and in mid-2013 management engaged Evli Corporate Finance to explore strategic alternatives aimed at maximizing shareholder value, with Dr. Daniel Chain now described in company materials as the former Chairman and CEO.

Name

Intellect Neurosciences

Legal name

Intellect Neurosciences, Inc.

Website

https://intellectns.com

Company type

Public

Founded year

2005

Operating status

Operating

Headcount range

1–10 employees

Short description

Intellect Neurosciences is a Manhattan-based, clinical-stage biopharmaceutical company that develops immunotherapies and antibody-drug conjugates for Alzheimer's disease, Friedreich's Ataxia, and AMD, licensing its drug programs to large pharmaceutical companies for milestone and royalty revenue.

Ownership category

akta.pro rank

Product category

Neurological Therapeutics / Biopharmaceutical Drug Development

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

akta.pro secondary industries

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC), Ophthalmology Specialty Pharmaceuticals (HLAIACAK)

Keywords

• Biopharmaceutical drug development
• Neurological disorder therapeutics
• Immunotherapy drug platforms
• Alzheimer's disease treatments
• Pharmaceutical licensing deals

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Licensing and Milestone Payments: The company licenses its drug development programs to large pharmaceutical companies. Intellect could receive up to $120 million in milestone payments from ViroPharma for the Friedreich's Ataxia program, with potential double digit royalties from sales over many years if products are successfully developed and commercialized.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

Intellect Neurosciences is a biopharmaceutical company developing disease-modifying immunotherapeutic drugs for proteinopathies affecting the brain and eye, including Alzheimer's disease, Friedreich's Ataxia, and age-related macular degeneration. The company operates three proprietary platform technologies — ANTISENILIN®, RECALL-VAX™, and CONJUMAB-A — plus the TOC-1 monoclonal antibody, and licenses these drug candidates to major pharmaceutical companies for clinical development and commercialization in exchange for milestone payments and royalties.

Product overview

Intellect Neurosciences is a biopharmaceutical company developing a pipeline of disease-modifying therapeutic drugs focused on proteinopathies affecting the brain and eye. The company operates three core technology platforms: ANTISENILIN® (for Alzheimer's disease targeting amyloid beta), RECALL-VAX™ (neoepitope-based immunotherapy), and CONJUMAB-A (antibody drug conjugates with anti-oxidant and anti-inflammatory activities). Additionally, the TOC-1 monoclonal antibody targets pre-fibrillar tau aggregates. The company's business model involves advancing drug development programs to value inflection points for licensing to large pharmaceutical companies, with intellectual property spanning global markets.

Differentiator

Problem solved

Functional benefit

Brands

• ANTISENILIN®: Technology platform for the treatment and prevention of Alzheimer's disease
• RECALL-VAX™
• CONJUMAB-A

Products and services

• ANTISENILIN®

Quantifiable outcome

• Multiple drugs in Phase 1, Phase 2 and Phase 3 clinical trials by major pharmaceutical companies

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered minor and core.

• Chain Pharmaceuticals LLCminorStrategic or Co-development Partner · 30 July 2013Intellect Neurosciences retained Chain Pharmaceuticals LLC for strategic consulting services.
• ViroPharmacoreStrategic or Co-development Partner · 1 January 2013Licensing transaction with ViroPharma for Friedreich's Ataxia program. ViroPharma plans to enter Phase 2 clinical trials in patients with Friedreich's Ataxia, an orphan indication. Intellect could receive up to $120 million in milestone payments and double digit royalties from sales over many years if the product is successfully developed and commercialized.

Scale indicators4 records

Recent moves2 records

Expansion highlights5 records

Direct peers

• Axonyx Inc. Formerly listed small-cap CNS biopharma that developed compounds for Alzheimer's and other cognitive disorders (subsequently went private/restructured) — comparable in size, scope, and historical positioning as a micro-cap CNS drug developer.
• AC Immune SA: Swiss biopharma developing small molecules, antibodies and vaccines targeting misfolded proteins such as amyloid-beta and tau in Alzheimer's and other neurodegenerative diseases — directly comparable platform mix (including RECALL-VAX-style vaccines) and licensing-led model.
• Prothena Corporation: Clinical-stage biotechnology company developing antibody-based therapeutics for neurodegenerative diseases driven by misfolded proteins (proteinopathies), including Alzheimer's and other CNS indications — directly comparable on modality (antibodies), target biology (misfolded proteins) and disease focus.
• Cognition Therapeutics: Clinical-stage CNS company developing small-molecule therapeutics that target the amyloid-beta pathway for Alzheimer's disease — directly comparable in CNS/Alzheimer's drug development with a similar small-team, partner-financed posture.
• TauRx Therapeutics: Private CNS biotech developing tau aggregation inhibitors for Alzheimer's disease and related dementias — comparable small, specialized tau-targeting organization with a pipeline centered on a single disease-modifying mechanism.
• EIP Pharma: CNS-focused biopharma developing therapeutics for neurodegenerative diseases including dementia — comparable small private CNS company pursuing mechanism-driven disease-modifying drugs for cognitive disorders.
• Probiodrug AG: European biopharma focused on amyloid-beta modification (pyroglutamate Aβ) for Alzheimer's disease — directly comparable single-mechanism CNS focus with a small-cap, asset-light development model.

Broad incumbents

• Biogen Inc. Large global biopharmaceutical company with a major Alzheimer's and neuroscience franchise (e.g., aducanumab) — relevant as a broad incumbent that both competes for partner attention and represents a potential acquirer of small CNS biotechs.

Others

• Mindset BioPharmaceuticals: Earlier private CNS biopharmaceutical company founded by Dr. Daniel Chain in 1999 prior to Intellect — comparable on founder, scientific lineage and therapeutic area focus, providing direct historical precedent for the platform's origin.

Emerging players

• C2N Diagnostics: Developer of tau-targeted diagnostics and therapeutics for Alzheimer's and related neurodegenerative disorders — comparable on tau biology overlap with the TOC-1 program and on proteinopathy-driven CNS strategy.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/intellect-neurosciences-inc.

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Intellect Neurosciences